top of page

FDA puts a hold on Seattle Genetics's Phase I trial of anti-CD33 antibody-drug conjugate

Dec 27, 2016
1 min read

Comments

Featured Posts

Recent Posts

SITC 2019 Scientific Highlights - Nov. 7

The gut microbiome’s role in immunity

The contraceptive device Essure, sounds like a dangerous product

Evidence of human domestication of dogs 8,000 years ago

Mutational load is only piece of the immunotherapy puzzle

A scientific first, and a step towards potentially dangerous territory. The time is right for the sc

Today will be a good day

Success with anti-PD-1 treatment of Colorectal cancer

FDA puts a hold on Seattle Genetics's Phase I trial of anti-CD33 antibody-drug conjugate

The landscape just keeps changing. So what's the best immunotherapy option for 2nd-line NSCLC?

Archive

Search By Tags

Follow Us

bottom of page